Talphera (NASDAQ:TLPH) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Talphera (NASDAQ:TLPH) announced its quarterly earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03, Zacks reports.

Here are the key takeaways from Talphera’s conference call:

• Talphera said the NEPHRO CRRT study is progressing well, with enrollment now well above the 50% milestone and the company still expecting to complete enrollment in 2026.
• Management reiterated plans to file the PMA in 2026 and still targets a potential Niyad approval in 2027, saying the company is positioned for that timeline.
• The company said it does not plan additional enrollment updates before study completion; it expects to announce last patient out, then release top-line data within about a month afterward.
• Talphera ended the quarter with $21.1 million in cash and said that, along with future conditional tranches, should fund operations through at least a potential PMA approval next year.
• Cash operating expenses rose to $3.9 million from $2.9 million a year ago, driven mainly by higher Niyad development spending and some increased G&A costs.

Talphera Stock Performance

NASDAQ TLPH traded down $0.03 during trading on Friday, reaching $0.87. The company’s stock had a trading volume of 41,870 shares, compared to its average volume of 217,543. The firm has a market cap of $45.00 million, a price-to-earnings ratio of -2.80 and a beta of 0.79. Talphera has a twelve month low of $0.38 and a twelve month high of $1.57. The business’s fifty day moving average price is $0.81 and its 200-day moving average price is $1.00.

Analyst Ratings Changes

TLPH has been the topic of several research analyst reports. Westpark Capital initiated coverage on shares of Talphera in a research note on Thursday, April 30th. They set a “buy” rating and a $3.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.00.

Insider Buying and Selling

In related news, CEO Vincent J. Angotti purchased 213,310 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average price of $0.59 per share, for a total transaction of $125,852.90. Following the transaction, the chief executive officer directly owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. The trade was a 36.31% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Talphera

Several institutional investors have recently added to or reduced their stakes in TLPH. Group One Trading LLC increased its position in Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after acquiring an additional 29,500 shares during the period. Virtu Financial LLC acquired a new position in Talphera in the 3rd quarter valued at about $29,000. Persistent Asset Partners Ltd acquired a new position in Talphera in the 4th quarter valued at about $42,000. Mariner LLC increased its position in Talphera by 132.0% in the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after acquiring an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC acquired a new position in Talphera in the 3rd quarter valued at about $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.